フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in C ...
Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd t ...
Hutchmed (China) Limited 02 January 2025 Overseas Regulatory Announcement - Disposal Transaction HUTCHMED (China) Limited ("HUTCHMED...
Hutchmed (China) Limited 02 January 2025 HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - HUTCHMED continues to...
Hutchmed (China) Limited 31 December 2024 Appointment of Cavendish as Joint Corporate Broker in London Hong Kong, Shanghai & Florham...
Hutchmed (China) Limited 30 December 2024 Blocklisting Six Monthly Return Hong Kong, Shanghai & Florham Park, NJ - Monday, December 30...
Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pha ...
Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endomet ...
Hutchmed (China) Limited 29 November 2024 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Friday, November 29, 2024:...
Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Taked ...
Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee ...
Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical ...
Hutchmed (China) Limited 31 October 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ – Thursday, October 31, 2024:...
Hutchmed (China) Limited 21 October 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in ...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約